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OBJECTIVE — Endothelial dysfunction is frequently present in individuals with insulin re-
sistance or type 2 diabetes and can be induced by high-fat or high-carbohydrate meals. Because
exenatide reduces postprandial glucose and lipid excursions, we hypothesized that it may also
improve postprandial endothelial function.
RESEARCH DESIGN AND METHODS — In a double-blinded randomized crossover
design,postprandialendothelialfunctionwasexaminedin28individualswithimpairedglucose
toleranceorrecent-onsettype2diabetesafterasingleinjectionofexenatideorplacebogivenjust
before a high-fat meal. Endothelial function was determined with peripheral arterial tonometry
pre- and postprandially.
RESULTS — Postprandial endothelial function was higher after exenatide compared with
placebo (P  0.0002). In the placebo phase, postprandial change in endothelial function was
inversely associated with mean postprandial concentrations of triglycerides (r  0.62, P 
0.0004).Changesinpostprandialtriglycerideconcentrationsexplained64%ofexenatide’seffect
on postprandial endothelial function.
CONCLUSIONS — Exenatide ameliorates postprandial endothelial dysfunction after a
high-fat meal.
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E
ndothelial dysfunction frequently
occurs in insulin resistance and type
2 diabetes (1) and can be induced by
high-fat or high-carbohydrate meals (2).
Recent data indicate that exenatide, a di-
abetes medication that lowers glucose
predominantly through postprandial ac-
tions (3,4), may also reduce postprandial
lipid excursions (5,6). The present study
investigated whether exenatide would
improve postprandial endothelial func-
tion in individuals with impaired glucose
tolerance (IGT) and recent type 2
diabetes.
RESEARCH DESIGN AND
METHODS— All participants pro-
vided written informed consent before
participationinthestudyapprovedbythe
local institutional review board. Eligibil-
itycriteriaincludedage35–70years,fast-
ing triglycerides 1.6–5.6 mmol/l, IGT or
dietcontrolled(A1C7.5%),andrecent-
onset (3 years) type 2 diabetes. The
study consisted of two clinical research
unit test periods separated by 1–3 weeks,
both commenced in the morning after an
overnight fast. Participants rested in a re-
cumbentpositioninaquietanddarkened
room for at least 15 min before measure-
ment of endothelial function by reactive-
hyperemia peripheral arterial tonometry
(PAT) (7). A double-masked subcutane-
ous injection of exenatide (10 g; Amylin
Pharmaceuticals, San Diego, CA) or nor-
mal saline was then administered in the
lower right abdominal quadrant. Within
15 min after the injection, the participants
consumed a standardized solid meal (600
kcal/m
2;45%fat[60%saturated],40%car-
bohydrates, 15% protein). Blood samples
were collected at 120 and 240 min and re-
active-hyperemia PAT was repeated 210
min after meal ingestion. The effects of ex-
enatide were evaluated by repeated-
measure ANCOVA using the SAS program
(version 9.2; SAS, Cary, NC). Further de-
tails on participants and methods are avail-
able in the online appendix (available at
http://care.diabetesjournals.org/cgi/content/
full/dc09-1961/DC1).
RESULTS— Baselinecharacteristicsof
thestudygroupareshowninsupplemen-
tal Table 1. Transient nausea after inges-
tion of the study meal tended to occur
more frequently, as expected, with ex-
enatide (n  14) than with placebo (n 
3). All but ﬁve subjects ingested their en-
tire meal on both occasions; four of these
ingested lower amounts during the pla-
cebo phase.
In the entire cohort, postprandial
PAT index (adjusted for baseline) was
higher after exenatide than after pla-
cebo (Fig. 1A). In subset analyses by
glucose tolerance, in individuals with
IGT (n  16), PAT index remained un-
changed after the meal during the pla-
cebo phase, tended to increase after
exenatide (P  0.1), and was higher
compared with the placebo period (Fig.
1B). Among individuals with type 2 di-
abetes (n  12), postprandial PAT in-
dex declined during the placebo phase
(P  0.006); this decline was largely
prevented by exenatide, and postpran-
dialendothelialfunctionafterexenatide
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1C). However, the improvement in
postprandial PAT index conferred by
exenatide was similar between these
two subgroups (P  0.7 for the effect of
glucose tolerance status in the entire
cohort).
Exenatide reduced postprandial rises
in glucose, insulin, and triglyceride con-
centrations(supplementalTable2).Inthe
placebo phase, postprandial PAT index
inversely correlated with mean (average
of 2 and 4 h) postprandial concentrations
of triglycerides (r  0.62, P  0.0004),
whereas it was not associated with post-
prandial glucose (r  0.29, P  0.1) or
insulin concentrations (P  1.0). In mul-
tivariate analysis, mean postprandial trig-
lycerides but not glucose or insulin
concentrations signiﬁcantly predicted
postprandial change in PAT index. Change
in postprandial triglycerides after exenatide
accountedfor64%oftheestimatedeffectof
exenatideonpostprandialendothelialfunc-
tion (supplemental Fig. 1).
CONCLUSIONS — The present data
conﬁrmed marked postprandial impair-
ment of endothelial function in individu-
als with type 2 diabetes (2) and suggest
that this susceptibility may develop early
in the evolution of diabetes, since a post-
prandial decline in endothelial function
was seen in patients with newly diag-
nosed diabetes and was absent in patients
with IGT. Most importantly, a single ex-
enatide injection improved postprandial
endothelial function in the overall group,
and the degree of postprandial endothe-
lial function improvement with exenatide
was similar in individuals with IGT and
diabetes.
Postprandial glucose and triglyceride
concentrations have been shown to be as-
sociated with endothelial dysfunction af-
ter meal challenges (2). In the present
study, improvement of postprandial en-
dothelial function after exenatide was re-
lated to declines in triglyceride but not
glucose concentrations. This could be ex-
plained by the predominantly high-fat
content of the meal resulting in a rela-
tively small postprandial increment in se-
rum glucose concentrations and by a
sample size that did not permit detection
of such a modest effect. Although almost
two-thirds of the effect of exenatide on
postprandial endothelial function in the
present study was accounted for by
changes in postprandial triglycerides, the
unexplained residual portion leaves open
the possibility that exenatide also im-
proves endothelial function by additional
mechanisms. In fact, glucagon-like pep-
tide-1 has been shown to improve vascu-
larfunctionindependentlyofitsactionon
glucose, lipid, or energy metabolism both
ex vivo, in preconstricted pulmonary ar-
teries(8),andinvivo,insalt-sensitivehy-
pertensive rats (9), in healthy humans
(10), and in subjects with type 2 diabetes
(11).
The systemic character of endothelial
dysfunction supports the use of endothe-
lial function measured on peripheral ar-
teries as a reasonable surrogate of
Figure1—DataaremeansSE.Theeffectsofexenatideandplaceboonpostprandialendothelial
function (PAT index) in the entire cohort (A) and in subjects with IGT (B) or type 2 diabetes (C).
Endothelial function was measured before and after a single high-fat breakfast meal. Participants
received placebo and exenatide on separate visits in a crossover design. P values denote statistical
signiﬁcance of differences in postmeal values (adjusted for pre-meal and test sequence) between
exenatide and placebo.
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lial function measured by reactive-
hyperemia PAT correlates well with
coronary endothelial function (12) and
with standard cardiovascular risk factors
(13). Because this study investigated the
effect of a single exenatide injection on
3.5-h postmeal endothelial function, we
cannot conclude that endothelial func-
tion will be improved throughout the day
with typical morning and evening ex-
enatideadministration.Infact,asamorn-
ing injection of exenatide appears to
decrease triglyceride levels after a morn-
ing meal but not after a noon meal (6), it
remains unclear whether the favorable ef-
fect of exenatide on endothelial function
would be preserved at mid-day. This will
presumably depend in part on whether
there are vascular beneﬁts of exenatide by
pathways that are independent of its trig-
lyceride-lowering effects. Finally, as our
study included only individuals with IGT
orrecenttype2diabeteswithoptimalgly-
cemic control, we cannot assume that ex-
enatide will improve endothelial function
in individuals with a longer history of di-
abetes, in whom the extent of vasculature
injury may be more advanced and less re-
sponsive to intervention.
Asendothelialdysfunctionappearsto
be an early indicator of vascular damage
and predicts both progression of athero-
sclerosis (14) and incidence of cardiovas-
cular events (15), exenatide and possibly
other incretin-based strategies may pro-
vide additional cardiovascular beneﬁt be-
yond improved glycemic control.
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